keyword
MENU ▼
Read by QxMD icon Read
search

SEER AND lung cancer

keyword
https://www.readbyqxmd.com/read/28195651/early-estimates-of-seer-cancer-incidence-2014
#1
Denise Riedel Lewis, Huann-Sheng Chen, Myles G Cockburn, Xiao-Cheng Wu, Antoinette M Stroup, Douglas N Midthune, Zhaohui Zou, Martin F Krapcho, Daniel G Miller, Eric J Feuer
BACKGROUND: Cancer incidence rates and trends for cases diagnosed through 2014 using data reported to the Surveillance, Epidemiology, and End Results (SEER) program in February 2016 and a validation of rates and trends for cases diagnosed through 2013 and submitted in February 2015 using the November 2015 submission are reported. New cancer sites include the pancreas, kidney and renal pelvis, corpus and uterus, and childhood cancer sites for ages birth to 19 years inclusive. METHODS: A new reporting delay model is presented for these estimates for more consistent results with the model used for the usual November SEER submissions, adjusting for the large case undercount in the February submission...
February 14, 2017: Cancer
https://www.readbyqxmd.com/read/28156628/management-of-the-primary-site-in-stage-iv-non-small-cell-lung-cancer-seer-analysis
#2
Savita V Dandapani
: 52 Background: One of every three non-small cell lung cancer (NSCLC) patients is diagnosed with terminal stage IV disease. As systemic treatments have evolved, other tumor sites such as kidney have demonstrated benefits of aggressive management of the primary location and oligo-metastases. The purpose of this study is to use the SEER database to evaluate survival outcomes associated with surgery (S) and radiation treatment (RT) of the primary site in stage IV NSCLC. METHODS: Eligible patient cases had lung coded as the primary location...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28156501/using-cancer-registry-records-linked-with-health-insurance-records-to-measure-costs-and-services-at-end-of-life
#3
Catherine R Fedorenko, Kristine Stickney, Cara L McDermott, Ted Conklin, Bruce Smith, Gary H Lyman, Scott David Ramsey
: 186 Background: Studies suggest that end-of-life (EOL) care for persons with cancer in the United States is variable and often misaligned with patient and family preferences. To better understand these issues, we developed reports on high-priority quality indicators and costs at EOL. METHODS: Surveillance, Epidemiology, and End Results (SEER) records for solid tumor patients diagnosed with cancer in Western Washington state between 1/1/2007 and 12/31/2015 were linked with enrollment and claims from two regional commercial insurers...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152886/impact-of-precancer-multimorbidity-clusters-on-survival-and-functional-outcomes-after-cancer-in-older-patients
#4
Joshua Richman, Erin E Kent, Maria Pisu, Smita Bhatia
: 291 Background: While multimorbidity clustering is a significant problem in older adults, the impact of clusters present prior to cancer on post-diagnosis survival and function is unknown. We used SEER-Medicare Health Outcomes Survey data for 4583 cancer patients to address this research gap. METHODS: Patients with prostate (1741), breast (BC: 1345), colorectal (CRC: 904) and lung (593) cancer with pre- and post-diagnosis survey data were included. Surveys assessed comorbidity and activities of daily living (ADLs)...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152784/breast-cancer-patient-functional-status-and-comorbidities-and-their-impact-on-treatment-aggressiveness-a-population-based-study
#5
Ramsankar Basak, Ronald C Chen
: 306 Background: The ASCO Choosing Wisely Campaign and other published guidelines recommend avoidance of aggressive treatments in early-stage cancer patients with limited life expectancy. However, patients with more advanced cancers are likely to benefit from aggressive treatment. The population-based SEER-MHOS (Medicare Health Outcomes Survey) provides unique data to allow assessment of aggressiveness of cancer treatment by cancer stage and patient frailty. METHODS: MHOS includes patient-reported functional deficits in a sample of Medicare beneficiaries, and has been linked with SEER data which provide diagnostic and treatment data...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152780/changing-patterns-of-care-for-locally-advanced-non-small-cell-lung-cancer-nsclc-implications-for-quality-initiatives
#6
Peter Edward Gabriel, Wensheng Guo, Sandhya Upasani, Marjorie van der Pas, Timothy E Schultheiss, Joel W Goldwein, John Paul Christodouleas
: 302 Background: Our purpose was to assess the utilization of dose escalated radiotherapy (RT) in Stage III NSCLC patients in the United States from 2004-2013, a period when no Level 1 evidence on dose escalation was published. METHODS: Data on all NSCLC patients treated with RT were extracted from the National Oncology Data Alliance (NODA), a pooled database of cancer registries from >150 US hospitals. The NODA contains the same data submitted to state cancer registries and SEER, but also contains RT dose fields that are manually verified by trained staff...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28149555/survival-after-subsequent-non-hodgkin-s-lymphoma-and-non-small-cell-lung-cancer-in-patients-with-malignant-thymoma
#7
Jacob S Parzen, James E Bates, Michael T Milano, Sughosh Dhakal
BACKGROUND: Survivors of malignant thymoma (MT) are at an increased risk of developing subsequent neoplasms. We compare overall survival (OS) between MT survivors who developed non-Hodgkin's lymphoma (NHL) or non-small cell lung cancer (NSCLC), and patients with first primary NHL (NHL-1) or NSCLC (NSCLC-1), respectively. METHODS: Using the population-based Surveillance, Epidemiology, and End Results (SEER) database for 1973 through 2013, 273,313 patients who had NHL-1, 21 patients with MT-NHL, 566,819 patients with NSCLC-1, and 38 patients with MT-NSCLC were identified...
December 2016: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28045621/antineoplastic-treatment-of-advanced-stage-non-small-cell-lung-cancer-treatment-survival-and-spending-2000-to-2011
#8
Cathy J Bradley, K Robin Yabroff, Angela B Mariotto, Christopher Zeruto, Quyen Tran, Joan L Warren
Purpose Multiple agents for advanced non-small-cell lung cancer (NSCLC) have been approved in the past decade, but little is known about their use and associated spending and survival. Methods We used SEER-Medicare data for elderly patients with a new diagnosis of advanced-stage NSCLC and were treated with antineoplastic agents between 2000 and 2011 (N = 22,163). We estimated the adjusted percentage of patients who received each agent, days while on treatment, survival, and spending in the 12 months after diagnosis...
January 3, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28038448/the-prognosis-analysis-of-different-metastasis-pattern-in-patients-with-different-breast-cancer-subtypes-a-seer-based-study
#9
Haiyong Wang, Chenyue Zhang, Jingze Zhang, Li Kong, Hui Zhu, Jinming Yu
Studies on prognosis of different metastasis patterns in patients with different breast cancer subtypes (BCS) are limited. Therefore, we identified 7862 breast cancer patients with distant metastasis from 2010 to 2013 using Surveillance, Epidemiology, wand End Results (SEER) population-based data. The results showed that bone was the most common metastatic site and brain was the least common metastatic site, and the patients with HR+/HER2- occupied the highest metastasis proportion, the lowest metastasis proportion were found in HR-/HER2+ patients...
December 27, 2016: Oncotarget
https://www.readbyqxmd.com/read/28029318/impact-of-examined-lymph-node-count-on-precise-staging-and-long-term-survival-of-resected-non-small-cell-lung-cancer-a-population-study-of-the-us-seer-database-and-a-chinese-multi-institutional-registry
#10
Wenhua Liang, Jiaxi He, Yaxing Shen, Jianfei Shen, Qihua He, Jianrong Zhang, Gening Jiang, Qun Wang, Lunxu Liu, Shugeng Gao, Deruo Liu, Zheng Wang, Zhihua Zhu, Calvin S H Ng, Chia-Chuan Liu, René Horsleben Petersen, Gaetano Rocco, Thomas D'Amico, Alessandro Brunelli, Haiquan Chen, Xiuyi Zhi, Bo Liu, Yixin Yang, Wensen Chen, Qian Zhou, Jianxing He
Purpose We investigated the correlation between the number of examined lymph nodes (ELNs) and correct staging and long-term survival in non-small-cell lung cancer (NSCLC) by using large databases and determined the minimal threshold for the ELN count. Methods Data from a Chinese multi-institutional registry and the US SEER database on stage I to IIIA resected NSCLC (2001 to 2008) were analyzed for the relationship between the ELN count and stage migration and overall survival (OS) by using multivariable models...
December 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28024699/temporal-patterns-of-care-and-outcomes-of-non-small-cell-lung-cancer-patients-in-the-united-states-diagnosed-in-1996-2005-and-2010
#11
Filip Kaniski, Lindsey Enewold, Anish Thomas, Shakuntala Malik, Jennifer L Stevens, Linda C Harlan
INTRODUCTION: Lung cancer remains a common and deadly cancer in the United States. This study evaluated factors associated with stage-specific cancer therapy and survival focusing on temporal trends and sociodemographic disparities. METHODS: A random sample (n=3,318) of non-small cell lung cancer (NSCLC) patients diagnosed in 1996, 2005 and 2010, and reported to the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) program was analyzed...
January 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27999144/long-term-follow-up-of-patients-having-false-positive-multi-target-stool-dna-tests-after-negative-screening-colonoscopy-the-long-haul-cohort-study
#12
Thomas G Cotter, Kelli N Burger, Mary E Devens, Julie A Simonson, Kari L Lowrie, Russell I Heigh, Douglas W Mahoney, David H Johnson, David A Ahlquist, John B Kisiel
BACKGROUND: Studies of colorectal cancer (CRC) screening by multi-target stool DNA (MT-sDNA) show false positive (FP) rates of 7-13%. It is unclear whether FP patients are at increased long-term risk of adverse outcomes. METHODS: We compared subsequent clinical events among patients with apparent FP MT-sDNA to those in patients reported as true negative (TN). This was a retrospective cohort study of participants in pre-FDA approval MT-sDNA studies having non-advanced or negative baseline colonoscopy findings from a single referral-center...
December 20, 2016: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/27997301/treatment-burden-of-medicare-beneficiaries-with-stage-i-non-small-cell-lung-cancer
#13
Carolyn J Presley, Pamela R Soulos, Mary Tinetti, Victor M Montori, James B Yu, Cary P Gross
PURPOSE: To quantify the burden and complexity associated with treatment of Medicare beneficiaries with stage I non-small-cell lung cancer (NSCLC). METHODS: Using the SEER-Medicare database, we conducted a retrospective cohort study of Medicare beneficiaries who were diagnosed with stage I NSCLC from 2007 to 2011 and who were treated with surgery, stereotactic body radiation therapy, or external beam radiation therapy. Main outcome measures were the number of days a patient was in contact with the health care system (encounter days), the number of physicians involved in a patient's care, and the number of medications prescribed...
December 20, 2016: Journal of Oncology Practice
https://www.readbyqxmd.com/read/27969457/mini01-08-disparities-in-the-management-of-patients-with-stage-i-small-cell-lung-cancer-sclc-a-surveillance-epidemiology-and-end-results-seer-analysis-topic-surgery
#14
Zaheer Ahmed, Lara Kujtan, Sashidhar Manthravadi, Kevin F Kennedy, John R Davis, Janakiraman Subramanian
No abstract text is available yet for this article.
November 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27956436/cancer-incidence-and-survival-trends-by-subtype-using-data-from-the-surveillance-epidemiology-and-end-results-program-1992-2013
#15
Anne-Michelle Noone, Kathleen A Cronin, Sean F Altekruse, Nadia Howlader, Denise R Lewis, Valentina I Petkov, Lynne Penberthy
BACKGROUND: Cancers are heterogeneous comprising of distinct tumor subtypes. Therefore, presenting the burden of cancer in the population and trends over time by these tumor subtypes is important to identify patterns and differences in the occurrence of these subtypes, especially to generalize findings to the US general population. METHODS: Using SEER cancer registry data, we present incidence rates according to subtypes for diagnosis years (1992-2013) among men and women for five major cancer sites: breast (female only), esophagus, kidney and renal pelvis, lung and bronchus, and thyroid...
December 12, 2016: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/27925181/estimation-of-the-tumor-size-at-cure-threshold-among-aggressive-non-small-cell-lung-cancers-nsclcs-evidence-from-the-surveillance-epidemiology-and-end-results-seer-program-and-the-national-lung-screening-trial-nlst
#16
Deborah L Goldwasser
The National Lung Screening Trial (NLST) demonstrated that non-small cell lung cancer (NSCLC) mortality can be reduced by a program of annual CT screening in high-risk individuals. However, CT screening regimens and adherence vary, potentially impacting the lung cancer mortality benefit. We defined the NSCLC cure threshold as the maximum tumor size at which a given NSCLC would be curable due to early detection. We obtained data from 518,234 NSCLCs documented in the U.S. SEER cancer registry between 1988 and 2012 and 1769 NSCLCs detected in the NLST...
March 15, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/27882054/risk-of-cancer-among-commercially-insured-hiv-infected-adults-on-antiretroviral-therapy
#17
Jeannette Y Lee, Ishwori Dhakal, Corey Casper, Ariela Noy, Joel M Palefsky, Missak Haigentz, Susan E Krown, Richard F Ambinder, Ronald T Mitsuyasu
The objective of this study was to explore the cancer incidence rates among HIV-infected persons with commercial insurance who were on antiretroviral therapy and compare them with those rates in the general population. Paid health insurance claims for 63,221 individuals 18 years or older, with at least one claim with a diagnostic code for HIV and at least one filled prescription for an antiretroviral medication between January 1, 2006, and September 30, 2012, were obtained from the LifeLink® Health Plan Claims Database...
2016: Journal of Cancer Epidemiology
https://www.readbyqxmd.com/read/27864324/colorectal-cancer-is-a-leading-cause-of-cancer-incidence-and-mortality-among-adults-younger-than-50%C3%A2-years-in-the-usa-a-seer-based-analysis-with-comparison-to-other-young-onset-cancers
#18
Abhishek Bhandari, Melissa Woodhouse, Samir Gupta
Colorectal cancer (CRC) incidence and mortality are rising among young adults. Our aim was to contrast the relative incidence and mortality of CRC to other common cancers among young adults in the USA. We used Surveillance, Epidemiology, and End Results registry data to compare cancer site-specific and age-specific mortality and incident rates for adults younger than age 50. We summarized extracted data, both overall, and stratified by sex. We found CRC was the third leading cause of cancer death among adults younger than age 50, after breast and lung cancer (1...
November 18, 2016: Journal of Investigative Medicine: the Official Publication of the American Federation for Clinical Research
https://www.readbyqxmd.com/read/27831506/causes-of-death-among-cancer-patients
#19
N G Zaorsky, T M Churilla, B L Egleston, S G Fisher, J A Ridge, E M Horwitz, Je Meyer Md
BACKGROUND: The purpose of our study was to characterize the causes of death among cancer patients as a function of objectives: (I) calendar year, (II) patient age, and (III) time after diagnosis. PATIENTS AND METHODS: US death certificate data in SEER Stat 8.2.1 were used to categorize cancer patient death as being due to index-cancer, non-index-cancer, and non-cancer cause from 1973 to 2012. In addition, data were characterized with standardized mortality ratios (SMRs), which provide the relative risk of death compared to all persons...
November 9, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27743073/addition-of-surgery-after-radiation-significantly-improves-survival-in-stage-iiib-non-small-cell-lung-cancer-a-population-based-analysis
#20
Alex Herskovic, Bhargava Chitti, Paul Christos, A Gabriella Wernicke, Bhupesh Parashar
OBJECTIVES: Limited work, either retrospective or prospective, has been done to investigate whether or not there is a cause-specific mortality (CSM) or all-cause mortality (ACM) benefit to adding surgery following neoadjuvant treatment for Stage IIIB NSCLC. METHODS: We extracted patients with Stage IIIB NSCLC from the Survival, Epidemiology, and End Results Program (SEER) database treated from 2004 to 2012 with either radiation alone or radiation followed by surgery...
October 14, 2016: World Journal of Surgery
keyword
keyword
68020
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"